BRITISH medical scheme
manager NHS England has received
guidance from the National
Institute for Health and Care
Excellence (NICE) around the use of
Kadcyla (trastuzumab-emtansine).
NICE has declared the HER2-
positive breast cancer therapy too
expensive at £90,000 per patient at
its full list price for routine use on
the NHS.
People currently taking Kadcyla
will not stop receiving it said NICE.
They have the option to continue
treatment until they and their
doctors consider it appropriate to
stop.The above article was sent to subscribers in Pharmacy Daily's issue from 21 Dec 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 21 Dec 15
RESEARCHERS at Charles Darwin University (CDU) are advancing a novel drug delivery system that could potentially eliminate the need for injections to treat various chronic diseases.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.